Harvard Medical School researchers have traced a possible biological path from the gut to depression, and it runs through the immune system. Their study, published in January 2025 in the Journal of the American Chemical Society, shows that a gut bacterium called Morganella morganii can react with a widespread environmental compound to create a molecule that turns on inflammation. The inflammatory signal it triggers, interleukin-6, is one of the most consistent immune markers found in people with major depressive disorder.
The compound is diethanolamine, or DEA, a chemical used across industrial, agricultural, and consumer products. When M. morganii encounters DEA in the gut, the bacterium builds it into an unusual phospholipid that mimics cardiolipin, a lipid the immune system reads as a danger signal.
"DEA's metabolism into an immune signal was completely unexpected," said Jon Clardy, the Christopher T. Walsh, PhD Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School and senior author of the study.
How a pollutant becomes an inflammation signal
The altered molecule turns on two immune sensors, TLR2 and TLR1, on the surface of immune cells. Once flipped on, those cells release cytokines, in particular interleukin-6, a protein that has been repeatedly tied to depression in genetic and clinical studies. Three separate meta-analyses have found that people with major depressive disorder tend to have elevated blood levels of IL-6 compared with people who are not depressed.
Also read: 8 warning signs of Lyme disease and when to see a doctor right away
M. morganii itself is not exotic. It lives in the human gut alongside many other microbes, and it has already been linked to inflammatory conditions such as type 2 diabetes and inflammatory bowel disease. What is new is the specific chemistry the Harvard team has drawn out, a step-by-step account of how the bacterium converts an environmental contaminant into an inflammatory cytokine.
Why this changes how depression is framed
The dominant public story about depression is still about serotonin and a "chemical imbalance" in the brain. That model does not fit every patient, and a growing body of research suggests that in a subset of people, depression behaves more like an inflammatory or immune-linked condition than a pure neurotransmitter problem. The new pathway offers one plausible reason why. If a gut microbe and a background pollutant can quietly generate an IL-6 signal for years on end, they could plausibly nudge mood and behavior in vulnerable people.
That would also help explain why some interventions aimed at the gut, including dietary changes that shift the microbiome, sometimes ease depressive symptoms.
What the study does and does not show
The findings are mechanistic. They describe a chain of chemistry, from a pollutant to a bacterial molecule to an immune signal, and they connect it to a marker already tied to depression. They do not show that removing M. morganii from the gut treats depression, and no clinical trial has tested that idea.
Also read: A brain stimulation device may slow Alzheimer's cognitive decline by nearly half
The practical value for now is a new target. Screening people with treatment-resistant depression for DEA exposure or for the abnormal phospholipid could, in principle, help identify a subgroup that might respond to immune-modulating drugs rather than to standard antidepressants.
Clardy said the door is now open to a broader search. "Now that we know what we're looking for, I think we can start surveying other bacteria to see whether they do similar chemistry and begin to find other examples of how metabolites can affect us," he said.
Anyone experiencing persistent low mood, loss of interest, sleep problems or hopelessness should speak with a doctor. Effective treatments for depression, including talk therapy and medication, are available today.
Also read: 8 warning signs of colorectal cancer most people mistake for stomach trouble
Also read: 1 in 3 adults has fatty liver disease. Scientists just found it comes in 5 distinct forms
This article is made and published by Jesper Bengtson, who may have used AI in the preparation.